Compare Annaly Capital Management, Inc. (NLY) vs Novartis AG (NVS) Price & Performance

Annaly Capital Management (NLY) trades at $22.72, down 0.39% for the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.751 estimate. Fundamentals show a high net income margin of 92.77% and a return on equity of 20.66%, though cash flow from operations declined to $692.91 million in 2025. Recent news includes a declared $0.75 dividend and a preferred stock redemption.

The outlook for NLY is supported by analyst consensus with a $24.33 price target and a majority buy rating, indicating potential upside. However, risks include significant investing cash outflows, high leverage with debt-to-asset ratio rising to 23.55 in 2025, and sensitivity to interest rate changes. The stock offers a high dividend yield but faces headwinds from mortgage rate volatility and tax inefficiencies for investors in taxable accounts.

Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.

The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.